Results 201 to 210 of about 321,774 (285)

Effects of Catastrophic Coverage Expansion on Out-of-Pocket Spending for Non-Covered Services and Financial Equity: Evidence from South Korea's National Health Insurance. [PDF]

Healthcare (Basel)
Kim M, Shin D, Shin H, Yoon J.
europepmc   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Is It Policy And Not Treatment That Actually Determines Epilepsy Outcomes? [PDF]

Epilepsy Curr
Ali A, McKee HR, Sisodiya SM.
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Decoding autonomy in digital work: how direct, indirect, and moderated effects shape health and burnout of social workers. [PDF]

BMC Public Health
Gnugesser E, Jöllenbeck M, Schlenger W, Ochsmann E.   +3 more
europepmc   +1 more source

Improved long-term care provision in the context of population ageing. [PDF]

Bull World Health Organ
Chhetri JK, Kamholz B, Chan P, Jang H, Sadana R.   +4 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Evaluating the impact of a medical telephone helpline and the use of a structured initial assessment on demand for acute and emergency care in Germany: an ecological study using secondary data. [PDF]

BMJ Open
Zoch-Lesniak B, Steiger E, Kroll LE, von Stillfried DG.   +3 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Huimin Insurance and unequal economic welfare between urban and rural areas: evidence from Chinese cities. [PDF]

Front Public Health
Ma J, Li S, Xue W.
europepmc   +1 more source